An Alzheimer's disease hypothesis based on transcriptional dysregulation

被引:32
作者
Robakis, NK
机构
[1] NYU, Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
[2] NYU, Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA
来源
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2003年 / 10卷 / 02期
关键词
Alzheimer's disease; transcription; A(2) peptide; amyloid;
D O I
10.3109/13506120309041729
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disorder of the central nervous system (CNS) characterized by progressive loss of memory and other cognitive skills. Neurons in the limbic and association cortices become progressively dysfunctional affecting almost all cognitive functions and memory. The PSI-regulated E-secretase cleavage of type I transmembrane receptors controls production of transcriptionally active intracellular fragments (ICFs) suggesting that this cleavage is a key factor in surface-to-nucleus signal transduction and gene expression. Signal-induced gene expression mediates neuronal responses to environmental changes and is a key event in neuronal survival and synaptic function. Familial Alzheimer's Disease (FAD) mutations may interfere with nuclear signaling and transcription by interfering with the PS1/epsilon-secretase cleavage and production of transcriptionally active ICFs. This raises the possibility that, similar to polyglutamine induced neurodegeneration like Huntington's chorea, transcriptional abnormalities are involved in the development Of FAD.
引用
收藏
页码:80 / 85
页数:6
相关论文
共 50 条
[41]   Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease [J].
Popugaeva, Elena ;
Pchitskaya, Ekaterina ;
Bezprozvanny, Ilya .
ANTIOXIDANTS & REDOX SIGNALING, 2018, 29 (12) :1176-1188
[42]   Emerging insights into synapse dysregulation in Alzheimer's disease [J].
Martinez-Serra, Raquel ;
Alonso-Nanclares, Lidia ;
Cho, Kwangwook ;
Giese, K. Peter .
BRAIN COMMUNICATIONS, 2022, 4 (02)
[43]   Complement dysregulation and Alzheimer's disease in Down syndrome [J].
Veteleanu, Aurora ;
Pape, Sarah ;
Davies, Kate ;
Kodosaki, Eleftheria ;
Hye, Abdul ;
Zelek, Wioleta M. ;
Strydom, Andre ;
Morgan, B. Paul .
ALZHEIMERS & DEMENTIA, 2023, 19 (04) :1383-1392
[44]   Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer's Disease [J].
Onukwufor, John O. ;
Dirksen, Robert T. ;
Wojtovich, Andrew P. .
ANTIOXIDANTS, 2022, 11 (04)
[45]   Dysregulation and Diagnostic Potential of microRNA in Alzheimer's Disease [J].
Pan, Yaoqian ;
Liu, Ruizhu ;
Terpstra, Erin ;
Wang, Yanqing ;
Qiao, Fangfang ;
Wang, Jin ;
Tong, Yigang ;
Pan, Bo .
JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (01) :1-12
[46]   Impacts of Iron Metabolism Dysregulation on Alzheimer's Disease [J].
Jouini, Najla ;
Saied, Zakaria ;
Ben Sassi, Samia ;
Nebli, Fatma ;
Messaoud, Taieb ;
Hentati, Faycel ;
Belal, Samir .
JOURNAL OF ALZHEIMERS DISEASE, 2021, 80 (04) :1439-1450
[47]   Dysregulation of BDNF in Prefrontal Cortex in Alzheimer's Disease [J].
Aarons, Toby ;
Bradburn, Steven ;
Robinson, Andrew ;
Payton, Antony ;
Pendleton, Neil ;
Murgatroyd, Chris .
JOURNAL OF ALZHEIMERS DISEASE, 2019, 69 (04) :1089-1097
[48]   The dysregulation of the cell cycle and the diagnosis of Alzheimer's disease [J].
Nagy, Zsuzsanna .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2007, 1772 (04) :402-408
[49]   NMDA and AMPA receptors dysregulation in Alzheimer's disease [J].
Babaei, Parvin .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 908
[50]   Epigenetic dysregulation in Alzheimer's disease: cause or consequence? [J].
van den Hove, Daniel L. A. ;
Kenis, Gunter ;
Rutten, Bart P. F. .
EPIGENOMICS, 2014, 6 (01) :9-11